Rigvir improves control and circulation of medicines

30 May 2019
For the purpose of control and circulation improvement of medicines, the registration of Rigvir in Latvia has been temporarily suspended, in order the validation of drug testing methods and related issues can be reorganized in accordance with the requirements of the State Agency of Medicines. Patients in Latvia who have already started virotherapy will have the opportunity to use a specially produced batch of medicines with a special permit of Agency and Health inspectorate of Latvia for the period of suspension.

Contacts for Media Inquiries

Rigvir Group
Address: 9-7 Teatra street, LV–1050, Riga, Latvia
Phone: +371 67 716 132
E-mail: pr@rigvir.com